AN2 Therapeutics, Inc.
ANTX
$4.27
-$0.45-9.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.17M | -33.99M | -37.38M | -45.35M | -51.32M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.18M | 5.11M | 5.69M | 5.37M | 5.06M |
| Change in Net Operating Assets | 164.00K | -991.00K | -3.81M | -2.30M | -3.00M |
| Cash from Operations | -29.83M | -29.87M | -35.50M | -42.29M | -49.26M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.31M | 14.26M | 26.87M | 37.49M | 54.59M |
| Cash from Investing | 28.31M | 14.26M | 26.87M | 37.49M | 54.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 113.00K | 113.00K | 88.00K | 88.00K | 372.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 113.00K | 113.00K | 88.00K | 88.00K | 372.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.41M | -15.50M | -8.55M | -4.71M | 5.70M |